Abstract
The success rate to achieve clinical approval of drugs developed to treat diseases of the central nervous system (CNS) is the lowest of all disease indications. A large contributor to this poor success rate is failure of small molecules to pass through the blood-brain barrier (BBB), a barrier composed of capillary endothelial cells connected by tight junctions that functions to extrude xenobiotics from the brain. Designing small molecules to be BBB penetrant has been the subject of intensive research and has resulted in a series of guidelines to attain the best possible chances of BBB penetration. This review will analyze the current state of thinking in ranking the importance of various physicochemical properties required to select BBB penetrant molecules, describe model systems to determine BBB penetration, summarize data analysis methods and provide an outlook on further developments in the field.
Keywords: Blood-brain barrier, Drug-likeness, Central Nervous System, Neuropharmacology, Physicochemical Properties, Drug Design.
Current Medicinal Chemistry
Title:Selecting Good ‘Drug-Like’ Properties to Optimize Small Molecule Blood-Brain Barrier Penetration
Volume: 23 Issue: 14
Author(s): Paul C. Trippier
Affiliation:
Keywords: Blood-brain barrier, Drug-likeness, Central Nervous System, Neuropharmacology, Physicochemical Properties, Drug Design.
Abstract: The success rate to achieve clinical approval of drugs developed to treat diseases of the central nervous system (CNS) is the lowest of all disease indications. A large contributor to this poor success rate is failure of small molecules to pass through the blood-brain barrier (BBB), a barrier composed of capillary endothelial cells connected by tight junctions that functions to extrude xenobiotics from the brain. Designing small molecules to be BBB penetrant has been the subject of intensive research and has resulted in a series of guidelines to attain the best possible chances of BBB penetration. This review will analyze the current state of thinking in ranking the importance of various physicochemical properties required to select BBB penetrant molecules, describe model systems to determine BBB penetration, summarize data analysis methods and provide an outlook on further developments in the field.
Export Options
About this article
Cite this article as:
C. Trippier Paul, Selecting Good ‘Drug-Like’ Properties to Optimize Small Molecule Blood-Brain Barrier Penetration, Current Medicinal Chemistry 2016; 23 (14) . https://dx.doi.org/10.2174/0929867323666160405112353
DOI https://dx.doi.org/10.2174/0929867323666160405112353 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy
Current Genomics Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Current Drug Targets Inflammatory Process as a Determinant Factor for the Degeneration of Substantia Nigra Dopaminergic Neurons: Possible Relevance to the Etiology of Parkinsons Disease
Current Medicinal Chemistry - Central Nervous System Agents Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease
Current Alzheimer Research Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Meta-Analysis of Creatine for Neuroprotection Against Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design Assessing the Effectiveness of a Telemedicine Initiative in Clinical Management of Children Living with HIV/AIDS in Maharashtra, India
Current HIV Research Editorial (Thematic Issue: Emerging Biomarkers for Drug Development in Amyotrophic Lateral Sclerosis)
Current Medicinal Chemistry Superoxide Dismutases: Anti- Versus Pro- Oxidants?
Anti-Cancer Agents in Medicinal Chemistry Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology An Update in the Management of Obesity: The Weight of CNS Targets
Recent Patents on CNS Drug Discovery (Discontinued) Chromosome 17 in Fronto Temporal Lobak Degeneration (FTLD): From MAPT to Progranulin and Back
Current Alzheimer Research Rational Design of Novel Potential p38α MAPK Inhibitors with Drug-like Properties Using Pharmacophore and Similarity-based Virtual Screening Procedures
Current Bioactive Compounds Editorial (Hot Topic: Targeting Histone Acetylation for Neuroprotection)
Current Pharmaceutical Design Phosphatidylserine and Curcumin Act Synergistically to Down-Regulate Release of Interleukin-1β from Lipopolysaccharide-Stimulated Cortical Primary Microglial Cells
CNS & Neurological Disorders - Drug Targets Mitochondrial Generation of Reactive Oxygen Species and its Role in Aerobic Life
Current Medicinal Chemistry Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Docking-Related Survey on Natural-Product-Based New Monoamine Oxidase Inhibitors and Their Therapeutic Potential
Combinatorial Chemistry & High Throughput Screening Pharmacophore-based Drug Design of Novel Potential Tau Ligands for Alzheimer's Disease Treatment
Current Physical Chemistry